Amneal Pharmaceuticals, Inc. AMRX Subtotal dosage forms — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported subtotal dosage forms — net revenue of $417.92M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue increased by 1.1% year-over-year, from $413.47M to $417.92M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s subtotal dosage forms — net revenue has grown at a 6.8% compound annual growth rate (CAGR), from $1.42B to $1.73B.
- What does subtotal dosage forms — net revenue mean?
- This metric represents the total gross sales generated from a specific category of pharmaceutical product delivery systems, adjusted for returns, allowances, and discounts. It serves as a key indicator of the market demand and commercial performance for the company's diverse portfolio of dosage forms. Tracking this revenue stream helps investors evaluate the segment's contribution to overall top-line growth and its competitive positioning within the broader generics market.